Table 2.

Distribution of different candidate genotype in relation to ASSP combination treatment.

No of isolates	kelch 13	atpase6 (263 + 431 + 623 + 6 30 + 769)	pfmdr1 (86 + 184 + 1034 + 1042 + 1246)	pfdhfr (16 + 51 + 59 + 108 + 164)	pfdhps (436 + 437 + 540 + 581 + 613)	pfcrt (72–76 + 326 + 356)	PC1/2		Parasite clearance time				Recrudescence	Ex-vivo AS (RSA) sensitivity
							< 5 h	> 5 h	≤ 36 h	> 36–≤ 48 h	> 48–≤ 72 h	> 72hETF	(LTF)	S	RS
21	Wild	LEAAS	NYSND	ANCSI	SAKAA	CVMNKNI	21	–	10	8	3	–	–	18	–
11	Wild	LEAAS	YYSND	ANCNI	SAKAA	CVMNTNI	11	–	7	2	2	–	–	10	–
6	Wild	LEAAS	NFSND	AICNI	SAKGA	SVMNTSI	6	–	2	4	–	–	–	4	–
16	Wild	LEAAS	NFSND	AICNI	SGKAA	SVMNTSI	15	1	5	6	5	–	–	14	–
7	Wild	LEAAS	YYSND	ANRNI	AAKAA	SVMNTNT	7	–	4	3	–	–	–	6
24	Wild	LEAAS	YYSND	AICNI	AGKAA	SVMNTNT	23	1	8	11	4	1	2	20	1
3	Wild	LEAAS	NFSND	AICTI	SGKAA	SVMNTSI	3	–	1	2	–	–	–	3	–
17	Wild	LEAAS	YYSND	AICNI	SGKAA	CVIETNT	17	–	4	11	2	–	–	16	–
6	N29L	LEAAS	NFSND	AICNI	AGKAA	SVMNTST	6	–	4	1	1	–	1	6	–
10	Wild	LEAAS	YYSND	ANRNI	SGKGT	SVMNTST	8	2	–	2	7	1a	2	6	1
3	Wild	LEEAS	NFSND	AICNI	SAKGA	SVMNTNT	3	–	–	3	–	–	–	3
5	Wild	LEAAS	NFSND	ANRNI	AGKAA	CVIETNT	5	–	–	3	2	–	1	5
5	Wild	LKAAS	YYSND	ANRNI	AGKAA	SVMNTNT	4	1	1	3	1	–	–	3	–
21	Wild	LEAAS	YFSND	AIRNI	SGKGT	SVMNTST	15	6	1	5	12	3	4	15	3
8	Wild	LEEAS	YFSND	AIRNI	AGKAA	SVMNTNT	6	2	–	2	4	2	1	6	1
3	A675V	LEAAS	NFSND	ANRNI	AGKAA	CVIETNT	2	1		1	2	–	1	–	3
14	Wild	LEAAS	YFSND	ANRNI	SGKGT	CVIETNT	11	3	–	5	7	2	–	10	2

Underlined codons are mutant codons. ETF and LTF stand for early treatment failure and late treatment failure, respectively, whereas S, and RS stand for sensitive, and reduced sensitivity, respectively. Parasite clearance half-life was denoted as PC_1/2.

^aPatients did not present adequate plasma dihydroartmisinin concentration, therefore not considered as true day-3 positive case.